Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

VYNE Therapeutics (VYNE) Return on Capital Employed (2018 - 2025)

VYNE Therapeutics' Return on Capital Employed history spans 8 years, with the latest figure at 0.95% for Q2 2025.

  • For Q2 2025, Return on Capital Employed fell 55.0% year-over-year to 0.95%; the TTM value through Jun 2025 reached 0.95%, down 55.0%, while the annual FY2025 figure was 0.64%, 0.0% changed from the prior year.
  • Return on Capital Employed reached 0.95% in Q2 2025 per VYNE's latest filing, down from 0.92% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 0.35% in Q1 2024 to a low of 2.23% in Q1 2021.
  • Average Return on Capital Employed over 5 years is 0.95%, with a median of 0.77% recorded in 2021.
  • Peak YoY movement for Return on Capital Employed: surged 250bps in 2021, then tumbled -57bps in 2025.
  • A 5-year view of Return on Capital Employed shows it stood at 0.7% in 2021, then tumbled by -43bps to 0.99% in 2022, then surged by 42bps to 0.57% in 2023, then tumbled by -34bps to 0.77% in 2024, then decreased by -24bps to 0.95% in 2025.
  • Per Business Quant, the three most recent readings for VYNE's Return on Capital Employed are 0.95% (Q2 2025), 0.92% (Q1 2025), and 0.77% (Q4 2024).